Autopsy Studies of COVID-19 Illness Rule Out Extensive Myocarditis

Systematic Review of 50 Studies with 548 Hearts Does not Find Heart Inflammation as Significant Contributor to Death



PETER A. MCCULLOUGH, MD, MPH™ 28 MAR 2023

♥ 443 Ø 16



By Peter A. McCullough, MD, MPH

From the original Baric study demonstrating beta-coronavirus loading in laboratory models can cause myocarditis to the first year of the COVID-19 crisis there has been a concern that SARS-CoV-2 infection in humans could cause heart inflammation. Epidemiologic studies relying on ICD codes triggered by routine cardiac troponin testing and or results implied that hospitalized patients were developing myocarditis with the respiratory illness. None of these studies were confirmed with clinical adjudication or autopsy. In 2020 the NCAA Big Ten athletic conference, US Military, and many other organizations screened for myocarditis on clinical grounds—handful of cases were found without any reported hospitalizations or deaths. Tuvali, et al from Israel, demonstrated that myocarditis in 2020 was not any more common that the low levels of baseline myocarditis from parvovirus, giant cell, and other conditions.

Almamlouk et al performed a systematic review of 50 autopsy studies and 548 hearts of patients who died of or with COVID-19. Usual post-mortem findings of tissue edema and necrosis were reported commonly. About two thirds of hearts had SARS-CoV-2 found in the tissue. However, none of the hearts had extensive myocarditis as the cause of death. a a companya a construction a constr

Contents lists available at ScienceDirect



Clinical Microbiology and Infection



journal homepage: www.clinicalmicrobiologyandinfection.com

Systematic review

COVID-19—Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review

Raghed Almamlouk ^{1,†}, Tarek Kashour ^{2,†}, Sawsan Obeidat ^{1,†}, Melanie C. Bois ³, Joseph J. Maleszewski ^{3,4}, Osama A. Omrani ^{5,6}, Rana Tleyjeh ¹, Elie Berbari ⁷, Zaher Chakhachiro ⁸, Bassel Zein-Sabatto ⁸, Dana Gerberi ⁹, Imad M. Tleyjeh ^{1,7,10,11,*}, on behalf of the Cardiac Autopsy in COVID-19 Study Group, Alberto E. Paniz Mondolfi ¹², Aloke V. Finn ¹³, Amaro Nunes Duarte-Neto ¹⁴, Amy V. Rapkiewicz ¹⁵, Andrea Frustaci ^{16,17}, Arthur-Atilla Keresztesi ¹⁸, Brian Hanley ^{19,20}, Bruno Märkl ²¹, Christelle Lardi ²², Clare Bryce ²³, Diana Lindner ^{24,25}, Diego Aguiar ²², Dirk Westermann ^{24,25}, Edana Stroberg ²⁶, Eric J. Duval ²⁶, Esther Youd ²⁷, Gaetano Pietro Bulfamante ^{28,29}, Isabelle Salmon ^{30,31,32}, Johann Auer ^{33,34}, Joseph J. Maleszewski ^{35,36}, Klaus Hirschbühl ³⁷, Lara Absil ³⁸, Lisa M. Barton ²⁶, Luiz Fernando Ferraz da Silva ^{14,39}, Luiza Moore ^{40,41}, Marisa Dolhnikoff ¹⁴, Martin Lammens ⁴², Melanie C. Bois ³⁵, Michael Osborn ^{19,43,44}, Myriam Remmelink ⁴⁵, Paulo Hilario Nascimento Saldiva ¹⁴, Philippe G. Jorens ^{46,47,48}, Randall Craver ⁴⁹, Renata Aparecida de Almeida Monteiro ¹⁴, Roberto Scendoni ⁵⁰, Sanjay Mukhopadhyay ⁵¹, Tadaki Suzuki ⁵², Thais Mauad ¹⁴, Tony Fracasso ²², Zachary Grimes ²³

ARTICLE INFO

Article history: Received 6 January 2022 Received in revised form 10 March 2022 Accepted 14 March 2022 Available online 23 March 2022

Editor: L. Leibovici

Keywords: Cardiac pathology COVID-19 Myocarditis Postmortem SARS-CoV-2 Systematic review

ABSTRACT

Background: Many postmortem studies address the cardiovascular effects of COVID-19 and provide valuable information, but are limited by their small sample size. Objectives: The aim of this systematic review is to better understand the various aspects of the cardiovascular complications of COVID-19 by pooling data from a large number of autopsy studies. Data sources: We searched the online databases Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science for concepts of autopsy or histopathology combined with COVID-19, published between database inception and February 2021. We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory. Study eligibility criteria: Articles were considered eligible for inclusion if they reported human postmortem cardiovascular findings among individuals with a confirmed SARS coronavirus type 2 (CoV-2) infection. Participants: Confirmed COVID-19 patients with post-mortem cardiovascular findings. Interventions: None. Methods: Studies were individually assessed for risk of selection, detection, and reporting biases. The median prevalence of different autopsy findings with associated interquartile ranges (IQRs). Results: This review cohort contained 50 studies including 548 hearts. The median age of the deceased was 69 years. The most prevalent acute cardiovascular findings were myocardial necrosis (median: 100.0%; IQR, 20%-100%; number of studies = 9; number of patients = 64) and myocardial oedema (median: 55.5%; IQR, 19.5%-92.5%; number of studies = 4; number of patients = 46). The median reported prevalence of extensive, focal active, and multifocal myocarditis were all 0.0%. The most prevalent chronic changes were myocyte hypertrophy (median: 69.0%; IQR, 46.8%-92.1%) and fibrosis (median: 35.0%; IQR, 35.0%-90.5%). SARS-CoV-2 was detected in the myocardium with median prevalence of 60.8% (IOR 40.4-95.6%). Conclusions: Our systematic review confirmed the high prevalence of acute and chronic cardiac pa-

Conclusions: Our systematic review confirmed the high prevalence of acute and chronic cardiac pathologies in COVID-19 and SARS-CoV-2 cardiac tropism, as well as the low prevalence of myocarditis in COVID-19. **Raghed Almamlouk, Clin Microbiol Infect 2022;28:1066**

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

R. Almamlouk et al. / Clinical Microbiology and Infection 28 (2022) 1066-1075

1069

Table 1

Summary of median prevalence of cardiac autopsy findings of studies with ≥5 patients

Autopsy finding	Pathology classification	Number of studies	Total number of patients	Median, %	Quarter 1, %	Quarter 3, %
Viral presence	Virology	10	116	60.8	40.4	95.6
Extensive myocarditis	Myocarditis	10	175	0.0	0.0	0.0
Focal active myocarditis	Myocarditis	13	235	0.0	0.0	13.4
Multifocal myocarditis	Myocarditis	9	131	0.0	0.0	2.1
Infiltrates without myocyte injury	Myocarditis	15	279	0.6	0.0	9.8
Pulmonary embolism	Thromboembolic	15	311	22.2	16.7	32.1
Microvessel thrombi	Thromboembolic	8	103	36.2	17.6	61.7
Cardiac large vessel thrombi	Thromboembolic	9	162	14.3	13.3	22.8
Acute myocardial infarction	Thromboembolic	7	104	11.8	7.9	13.8
Small vessel vasculitis	Inflammatory	3	86	28.6	16.0	32.5
Epi-pericarditis	Inflammatory	6	110	15.5	11.9	19.2
Cardiac oedema	Gross pathology	4	46	55.5	19.5	92.5
Managaia	Cross pathology	0	CA.	100.0	20.0	100.0

INECTOSIS	Gross pathology	9	04	100.0	20.0	100.0
Fibrosis	Chronic	13	183	42.9	35.0	90.5
Amyloidosis	Chronic	8	131	13.6	9.8	17.4
Atherosclerotic coronary artery disease	Chronic	14	250	46.2	21.6	80.1
Hypertrophy	Chronic	18	303	69.0	46.8	92.1

Hanley B, Märkl B, Lardi C, Bryce C, Lindner D, Aguiar D, Westermann D, Stroberg E, Duval EJ, Youd E, Bulfamante GP, Salmon I, Auer J, Maleszewski JJ, Hirschbühl K, Absil L, Barton LM, Ferraz da Silva LF, Moore L, Dolhnikoff M, Lammens M, Bois MC, Osborn M, Remmelink M, Nascimento Saldiva PH, Jorens PG, Craver R, Aparecida de Almeida Monteiro R, Scendoni R, Mukhopadhyay S, Suzuki T, Mauad T, Fracasso T, Grimes Z. COVID-19-Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. Clin Microbiol Infect. 2022 Aug;28(8):1066-1075. doi: 10.1016/j.cmi.2022.03.021. Epub 2022 Mar 23. PMID: 35339672; PMCID: PMC8941843.

In summary, this review should be the nail in the coffin in ruling out COVID-19 illness as a cause of fatal myocarditis. Despite the virus being found in heart tissue, it was not causing significant inflammation. The explosion of fatal myocarditis by report of unexplained cardiac arrest, adjudication, and at necropsy must have another explanation than SARS-CoV-2 infection. The only new proven cause of heart damage in human populations is COVID-19 vaccination. Vaccines used in America (Pfizer, Moderna, Janssen, Novavax) have been demonstrated to cause myocarditis as published in the peer-reviewed literature.

These observations call for immediate access to the CDC COVID-19 vaccine administration database for physicians and other providers who are managing the burgeoning caseload of myocarditis. This will be the only way the epidemiology of COVID-19 vaccine induced myocarditis can be studied and patient outcomes can be improved.

If you find "Courageous Discourse" enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, Jeudy J, Mattson SE, Law IH, Borchers J, Kovacs R, Kovan J, Rifat SF, Albrecht J, Bento AI, Albers L, Bernhardt D, Day C, Hecht S, Hipskind A, Mjaanes J, Olson D, Rooks YL, Somers EC, Tong MS, Wisinski J, Womack J, Esopenko C, Kratochvil CJ, Rink LD; Big Ten COVID-19 Cardiac Registry Investigators. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 Sep 1;6(9):1078-1087. doi: 10.1001/jamacardio.2021.2065. PMID: 34042947; PMCID: PMC8160916.

Tuvali O, Tshori S, Derazne E, Hannuna RR, Afek A, Haberman D, Sella G, George J. The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study. J Clin Med. 2022 Apr 15;11(8):2219. doi: 10.3390/jcm11082219. PMID: 35456309; PMCID: PMC9025013.

Almamlouk R, Kashour T, Obeidat S, Bois MC, Maleszewski JJ, Omrani OA, Tleyjeh R, Berbari E, Chakhachiro Z, Zein-Sabatto B, Gerberi D, Tleyjeh IM; Cardiac Autopsy in COVID-19 Study Group; Paniz Mondolfi AE, Finn AV, Duarte-Neto AN, Rapkiewicz AV, Frustaci A, Keresztesi AA, Hanley B, Märkl B, Lardi C, Bryce C, Lindner D, Aguiar D, Westermann D, Stroberg E, Duval EJ, Youd E, Bulfamante GP, Salmon I, Auer J, Maleszewski JJ, Hirschbühl K, Absil L, Barton LM, Ferraz da Silva LF, Moore L, Dolhnikoff M, Lammens M, Bois MC, Osborn M, Remmelink M, Nascimento Saldiva PH, Jorens PG, Craver R, Aparecida de Almeida Monteiro R, Scendoni R, Mukhopadhyay S, Suzuki T, Mauad T, Fracasso T, Grimes Z. COVID-19-Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. Clin Microbiol Infect. 2022 Aug;28(8):1066-1075. doi: 10.1016/j.cmi.2022.03.021. Epub 2022 Mar 23. PMID: 35339672; PMCID: PMC8941843.



16 Comments

Write a comment...

Karl Lambert Mar 29

We have had two calls from the CDC and I have instructed my staff to NOT to speak to anyone. We will only give them what they request in writing and that is it period. They are NOT TO BE TRUSTED. Since acquiring our Multifunction Cardiogram from heartcarecorp.com, we have filed 10 cases through openvaers.com to report myocarditis in our vaccinated patients. CDC has clearly picked up on this enough to call our small nurse practitioner owned practice in a rural community. Regardless, I will not speak with anyone from the CDC. Call it paranoia, but after 7 DOH complaints agaisnt my license during the covid plandemic--my guard and defenses are ALL UP.

1 reply



Kathleen Baggio Mar 28

Building the case incrementally, well done. I wonder what the "a ha" moment will finally be for those who continue to be hoodwinked. I can show ppl article after article and they just keep saying "so what - the best scientist in the world are on this and still recommend it".....as he is on his 4th. Good Grief.

1 reply

14 more comments...

© 2023 Peter McCullough MD MPH · <u>Privacy</u> · <u>Terms</u> · <u>Collection notice</u> <u>Substack</u> is the home for great writing